Business Description
Bioceltix SA
ISIN : PLBCLTX00019
Compare
Compare
Traded in other countries / regions
BCX.PolandXI3.Germany IPO Date
2021-12-07Description
Bioceltix SA develops therapies for veterinary use that harness the immunomodulatory properties of mesenchymal stem cells. Its pipeline products include BCX-CM-J for Degenerative joint lesions; BCX-CM-S for Autoimmune and inflammatory diseases in dogs; BCX-EM for Tendon damage and BCX-FM for Gingivostomatitis.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 95.41 | |||||
| Equity-to-Asset | 0.86 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -73.4 | |||||
| 3-Year EPS without NRI Growth Rate | -54.4 | |||||
| 3-Year FCF Growth Rate | -96.2 | |||||
| 3-Year Book Growth Rate | 35.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 23.93 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 47.16 | |||||
| 9-Day RSI | 50.1 | |||||
| 14-Day RSI | 49.64 | |||||
| 6-1 Month Momentum % | 0.98 | |||||
| 12-1 Month Momentum % | 16.61 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.27 | |||||
| Quick Ratio | 3.27 | |||||
| Cash Ratio | 2.87 | |||||
| Days Inventory | 2.72 | |||||
| Days Payable | 688.37 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.9 | |||||
| Shareholder Yield % | -4.89 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -83.97 | |||||
| ROA % | -71.08 | |||||
| ROIC % | -180.25 | |||||
| ROC (Joel Greenblatt) % | -1007.97 | |||||
| ROCE % | -83.04 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 8 | |||||
| Price-to-Tangible-Book | 7.87 | |||||
| EV-to-EBIT | -21.44 | |||||
| EV-to-EBITDA | -22.07 | |||||
| EV-to-FCF | -24.5 | |||||
| Price-to-Net-Current-Asset-Value | 22.48 | |||||
| Price-to-Net-Cash | 27.23 | |||||
| Earnings Yield (Greenblatt) % | -4.66 | |||||
| FCF Yield % | -3.89 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bioceltix SA Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.865 | ||
| Beta | 0 | ||
| Volatility % | 53.44 | ||
| 14-Day RSI | 49.64 | ||
| 14-Day ATR (€) | 1.024924 | ||
| 20-Day SMA (€) | 14.008 | ||
| 12-1 Month Momentum % | 16.61 | ||
| 52-Week Range (€) | 11.74 - 19.8 | ||
| Shares Outstanding (Mil) | 4.92 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bioceltix SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bioceltix SA Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Bioceltix SA Frequently Asked Questions
What is Bioceltix SA(FRA:XI3)'s stock price today?
The current price of FRA:XI3 is €14.16. The 52 week high of FRA:XI3 is €19.80 and 52 week low is €11.74.
When is next earnings date of Bioceltix SA(FRA:XI3)?
The next earnings date of Bioceltix SA(FRA:XI3) is .
Does Bioceltix SA(FRA:XI3) pay dividends? If so, how much?
Bioceltix SA(FRA:XI3) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers